AEON

AEON is a pre-revenue, clinical-stage biopharma whose entire value rests on ABP-450, a proposed Botox biosimilar that has never been approved or sold anywhere in the U.S. and generates zero revenue. The financials describe a company running on fumes: FY2025 cash of just $3.01M against operating cash burn of -$17.3M means well under a quarter of runway before it must raise money or halt. Stockholders' equity is negative at -$55.0M, with total liabilities of $60.6M dwarfing $5.56M of total assets and an accumulated deficit of -$470.8M. That is a balance sheet in the red, not merely a stretched one, and shares outstanding already jumped +140% to 25.3M, telegraphing severe dilution ahead for any capital raise at a $0.72 stock.

The headline history is a trap. FY2024's reported +$42.0M net income and $73.0M operating income were not operating success — the MD&A states they were driven by a $100.8M non-cash gain on fair value of contingent consideration. Strip the accounting, and this is a company that lost money every real year; even FY2025's -$12.8M operating loss flatters a -$16.3M loss from operations with a $3.5M fair-value gain. R&D fell -71% to $4.09M, consistent with a program being run on a shoestring after the May 2024 discontinuation of the ABP-450 migraine Phase 2 and the July 2024 pivot to the cheaper 351(k) biosimilar route.